Jump to navigation Jump to search
Clinical data
ATC code
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass248.155 g/mol

WikiDoc Resources for Triflusal


Most recent articles on Triflusal

Most cited articles on Triflusal

Review articles on Triflusal

Articles on Triflusal in N Eng J Med, Lancet, BMJ


Powerpoint slides on Triflusal

Images of Triflusal

Photos of Triflusal

Podcasts & MP3s on Triflusal

Videos on Triflusal

Evidence Based Medicine

Cochrane Collaboration on Triflusal

Bandolier on Triflusal

TRIP on Triflusal

Clinical Trials

Ongoing Trials on Triflusal at Clinical

Trial results on Triflusal

Clinical Trials on Triflusal at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Triflusal

NICE Guidance on Triflusal


FDA on Triflusal

CDC on Triflusal


Books on Triflusal


Triflusal in the news

Be alerted to news on Triflusal

News trends on Triflusal


Blogs on Triflusal


Definitions of Triflusal

Patient Resources / Community

Patient resources on Triflusal

Discussion groups on Triflusal

Patient Handouts on Triflusal

Directions to Hospitals Treating Triflusal

Risk calculators and risk factors for Triflusal

Healthcare Provider Resources

Symptoms of Triflusal

Causes & Risk Factors for Triflusal

Diagnostic studies for Triflusal

Treatment of Triflusal

Continuing Medical Education (CME)

CME Programs on Triflusal


Triflusal en Espanol

Triflusal en Francais


Triflusal in the Marketplace

Patents on Triflusal

Experimental / Informatics

List of terms related to Triflusal

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux [1]

Mechanism of action

Triflusal is a selective platelet antiaggregant through;


Triflusal is indicated for;

Prevention of Stroke

In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid plus dipyridamole, or clopidogrel alone for secondary prevention of atherothrombotic stroke. This recommendation was based on the double-blind, randomised TACIP and TAPIRSS trials, which found triflusal to be equally as effective as Aspirin in preventing post-stroke vascular events, while having a more favourable safety profile.[2][3][4]


It is absorbed in the small intestine and its bio-availability ranges from 83% to 100%.[5][6]


  1. Murdoch D, et al. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.Drugs 2006; 66(5):671-92
  2. Matías-Guiu J, Ferro JM, Alvarez J, et al; for the TACIP Investigators. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double-blind, multicenter trial. Stroke 2003; 34; 840-848
  3. Culebras A, Rotta-Escalante R, Vila J, et al; and the TAPIRSS investigators. Triflusal vs. aspirin for prevention of cerebral infarction.A randomized stroke study. Neurology. 2004; 62:1073-1080
  4. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. The European Stroke Organization(ESO) Executive Committee and the ESO Writing Committee.Cerebrovasc Dis. 2008; 25: 57-507
  5. Ramis J, Mis R, Conte L, Forn J. Rat and human plasma protein binding of the main metabolite of triflusal. Eur J Pharmacol.1990; 183: 1867-1868
  6. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jané F. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet.1991; 16: 169-273.37,38